Physitrack PLC (PTRK) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Physitrack PLC SEK 7.10, price SEK 8.90, upside -20.3%, quality 61 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Physitrack PLC for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range kr 7.36 – kr 70.00 · fair‑value band kr 4.00 – kr 13.18 · the kr 8.90 price screens above the kr 7.10 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Physitrack in your weekly email
Every Wednesday you see whether Physitrack is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Physitrack PLC, together with its subsidiaries, provides digital healthcare solutions in the United Kingdom, Europe, North America, and internationally. It operates through two segments, Lifecare and Wellness.
Show more
Physitrack PLC, together with its subsidiaries, provides digital healthcare solutions in the United Kingdom, Europe, North America, and internationally. It operates through two segments, Lifecare and Wellness. The company offers Physitrack, a remote therapeutic monitoring platform that provides a suite of tools for exercise program prescription, patient-reported adherence and tracking, and telehealth for private practices, occupational health and case management, healthcare systems and hospitals, and sports. It also offers Physiapp, a mobile application that allows physiotherapists to deliver personalized rehabilitation programs, track patient progress, and adjust treatments in real-time; and Physiocourses, an e-learning library for healthcare professionals. Physitrack PLC was incorporated in 2012 and is based in London, the United Kingdom.
Stock analysis
Physitrack PLC (PTRK) currently trades at kr 8.90, while our model-based Fair Value estimate is kr 7.10, implying the stock looks roughly 25.4% overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of kr 5.82 per share, and 0 of the 13 models we run sit above the kr 8.90 price.
Bear case: the Growth DCF group reads lowest at kr 1.97, and 13 of the 13 models stay below the price. Evidence for this calculation is low.
Scenario range: kr 4.00 (bear) to kr 13.18 (bull), the price of kr 8.90 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 61/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Physitrack PLC reported revenue of €13.8M in FY2025 versus €7.8M in FY2021, a compound +15.2%/yr. Reported net income was −€6.9M in FY2025.
Key figures
Market cap 145M SEK (≈ $14.6M) · P/S ratio 9.14 · EPS (TTM) kr −4.55 · Net margin −50.3% · Return on equity −43.0% · Return on assets (EBIT) −1.3% · Operating margin 7.7% · Revenue (TTM) €13.6M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).
What moves the price
The share trades about 54% below its 52-week high and 21% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −45% fair-value upside, at −20%, PTRK screens cheaper than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (kr 0.1000 to kr 7.73). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear kr 4.00Fair Value kr 7.10Bull kr 13.18
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.61/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−14.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.8%
Start year 2020 (pandemic). Over 10 years: +77.6% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+78.4%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
15.7% (2020) → 3.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−21.1%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (figures in EUR, euro area: IMF forecast 2.2% a year to 2030, 2.6% from 2016 to 2025) that is about −22.8% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 134 stocks
Beats the industry median on 7/10 measures
Overall it ranks above its industry peers.
Valuation
Quality Score61 · Above median
Fair Value upside−19% · Above median
Profitability
Return on assets2% · Above median
Net margin (TTM)−62% · Bottom 25%
Operating margin (TTM)8% · Above median
Growth and dividend
Revenue growth3% · Below median
Balance sheet
Debt / equity0.40× · Highest 25%
Valuation Multiplesvs Health Information Services median · lower = cheaper
P/B1.45× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Physitrack PLC Fair Value". https://www.fairvalue-calculator.com/stock/PTRK
Frequently asked questions
Is Physitrack PLC (PTRK) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of kr 7.10 versus a price of kr 8.90, about −20% upside (overvalued).
What is the fair value of PTRK?
Our model-based fair value for Physitrack PLC is kr 7.10 (as of Sep 24, 2026), built from audited fundamentals. The current price: kr 8.90.
What is the quality score of PTRK?
Physitrack PLC has a Quality Score of 61/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Physitrack PLC (PTRK)?
Our model-based price target is the fair value of kr 7.10 (as of Sep 24, 2026) from 13 valuation models. Cautious scenario kr 4.00, optimistic scenario kr 13.18. It is a calculation from audited fundamentals, not an analyst target.
What is the Physitrack PLC stock forecast for 2026?
Our models put fair value at kr 7.10, about −20% upside versus a price of kr 8.90 (overvalued). Cautious scenario kr 4.00, optimistic scenario kr 13.18. The calculation is refreshed regularly with new filings.
What is the revenue of Physitrack PLC (PTRK)?
Physitrack PLC reported trailing-twelve-month revenue of about €13.6M (latest available figure, as of Sep 24, 2026).
What growth is priced into Physitrack PLC (PTRK)?
For today's price to be fair in a discounted-cash-flow model, Physitrack PLC would have to grow free cash flow by -21.1 % per year for five years (discount rate 8.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +18.8 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of PTRK use?
Our models discount Physitrack PLC at 8.5 %: a base by market capitalisation (nano), damped by beta 0.57, country premium for Sweden. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Physitrack PLC that is -21.1 % per year a year over ten years, using the same discount rate (8.5 %) and the same formula as our fair value.
How much growth has Physitrack PLC (PTRK) delivered so far?
Over the past 5 years revenue at Physitrack PLC grew +18.8 % a year. The price currently implies -21.1 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Physitrack PLC (PTRK) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Physitrack PLC (-21.1 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Physitrack PLC (PTRK)?
The free-cash-flow yield on the price is 30.21 %: that much free cash flow Physitrack PLC produces per unit of market value. When it exceeds the discount rate of our models (8.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Physitrack PLC (PTRK)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Physitrack PLC it is kr 7.10 per share (as of Sep 24, 2026), against a price of kr 8.90. It is the blended result of 13 valuation models (cash flow, earnings, asset, dividend).
Is Physitrack PLC stock overvalued or undervalued in 2026?
As of Sep 24, 2026, PTRK trades above its calculated fair value: price kr 8.90, fair value kr 7.10, a gap of about −20% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PTRK?
No. The price is what the market pays today (kr 8.90); the fair value is what the company's own numbers justify (kr 7.10). For Physitrack PLC the two are kr 1.80 per share apart. That gap is exactly why we show both numbers side by side.
How much is Physitrack PLC worth?
The market values Physitrack PLC at about 145M SEK (market capitalisation, as of Sep 24, 2026). Per share that is kr 8.90; our models calculate a fair value of kr 7.10 per share.
What do the bullish and bearish scenarios say about PTRK?
Our models span a range for Physitrack PLC: cautious scenario kr 4.00, base kr 7.10, optimistic kr 13.18 per share (as of Sep 24, 2026, price kr 8.90). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Physitrack PLC (PTRK)?
Balance-sheet figures for Physitrack PLC (as of Sep 24, 2026): return on equity −43.0%, debt of 0.40 per unit of equity. They feed the Quality Score of 61/100, which measures business quality independently of the share price.
How far is PTRK from its 52-week high?
Physitrack PLC trades at kr 8.90, about 54% below its 52-week high of kr 19.25 and 21% above the low of kr 7.36 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of kr 7.10 is for.
Which stocks are comparable to Physitrack PLC?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, HealthEquity, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Physitrack PLC stock attractive at the current price?
The data as of Sep 24, 2026: price kr 8.90, calculated fair value kr 7.10 (−20%), Quality Score 61/100, from 13 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of PTRK calculated?
We run Physitrack PLC through 13 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 7.10, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Physitrack PLC itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Physitrack PLC (PTRK)?
The closing price on Sep 24, 2026 was kr 8.90. Our model-based fair value is kr 7.10, about −20% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Physitrack PLC right now?
The model range is unusually wide (kr 4.00 to kr 13.18). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid but not exceptional quality (61/100) and above fair value, neither a clear bargain nor a standout compounder. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Physitrack PLC
How large is the market capitalisation of Physitrack PLC (PTRK)?
The market capitalisation of Physitrack PLC is 145M SEK (≈ $14.6M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Physitrack PLC (PTRK)?
The price-to-sales ratio of Physitrack PLC is 9.14 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Physitrack PLC (PTRK)?
Earnings per share at Physitrack PLC are kr −4.55. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Physitrack PLC (PTRK)?
The net margin of Physitrack PLC is −50.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Physitrack PLC (PTRK)?
The return on equity (ROE) of Physitrack PLC is −43.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Physitrack PLC (PTRK)?
On an EBIT basis the return on assets of Physitrack PLC is −1.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Physitrack PLC (PTRK)?
The operating margin of Physitrack PLC is 7.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Physitrack PLC (PTRK)?
Revenue at Physitrack PLC is growing +3.3% versus a year earlier (3y avg +3.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Physitrack PLC (PTRK)?
Earnings per share at Physitrack PLC are growing +482% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Physitrack PLC (PTRK) carry?
The net debt of Physitrack PLC is €3.3M (fiscal year 2025, ≈ 0.8 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Physitrack PLC in the live analysis
One click puts Physitrack PLC on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
